Developing New Agents for Treatment of Childhood Cancer: Challenges and Opportunities for Preclinical Testing

Area of Science:

• Pediatric Oncology
• Translational Research
• Drug Development

Background:

• Pediatric cancers are rare, with ~12,500 U.S. diagnoses annually in individuals 18 or younger.
• High survival rates (80% 5-year event-free survival) limit patient numbers for experimental drug trials.
• Diverse disease entities (e.g., acute lymphoblastic leukemias, brain tumors) and molecular subtypes complicate research.

Purpose of the Study:

• To address challenges in developing new therapeutics for pediatric cancers.
• To examine limitations of current preclinical models in pediatric oncology.
• To explore approaches for improving preclinical model translatability to clinical trials.

Main Methods:

• Review of existing literature on pediatric cancer research and preclinical models.
• Analysis of challenges in clinical trial design for rare pediatric malignancies.
• Consideration of regulatory impacts, such as the RACE For Children Act.

Main Results:

• Pediatric cancer rarity and heterogeneity pose significant hurdles for drug development.
• Current preclinical models may not accurately represent diverse molecular subtypes of childhood cancers.
• The RACE For Children Act introduces new considerations for pediatric drug development.

Conclusions:

• Improving preclinical models is essential for accurately identifying effective pediatric cancer therapies.
• Enhanced models can better predict treatment response and facilitate successful clinical translation.
• Addressing model limitations is key to advancing novel therapeutic strategies for children with cancer.